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Dear Editor, 
p16INK4a protein (p16) is an important tumor 
suppressor protein involved in the carcinogenesis of 
many human malignancies. I have read with interest 
an article by Donati et al. (1) in this journal, who inves-
tigated an expression of p16 and proliferation marker 
Ki-67 in cutaneous tumors. Among them, there were 
27 cases of non-melanoma skin cancer (NMSC), 23 
of which comprised basal cell carcinoma (BCC), and 
4 squamous cell carcinoma (SCC) lesions. The au-
thors stated “in NMSC, they found a high prevalence 
(69.6%) of lesions with p16 expression between 34-
66%, while the remaining specimens showed p16 
expression ≤34%”. Although they did not specify the 
exact proportions of BCC and SCC, one may specu-
late that the majority of BCCs (and maybe all) were at 
least partly immunoreactive for p16. As the literature 
gives very contradictory data on this topic, herein I 
will present my personal observations in this field.
I performed immunohistochemical analysis of 
p16 in a set of 24 cutaneous BCCs obtained from 23 
patients. They were categorized into non-aggressive 
(4 superficial and 10 nodular subtypes) and aggres-
sive (7 nodular-infiltrative and 3 infiltrative subtypes) 
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subgroups. In all cases, monoclonal mouse antibody 
against p16 (clone G175-405, Zeta Corp., dilution 
1:75) was used for staining. Overall, I found 7 cases 
(29.1%) of BCCs manifesting a certain degree of p16-
immunoreactivity in the tumor tissue. These lesions 
arose on the head in four cases (4/17; 23.5%) and on 
the back and limbs in three cases (3/7; 42.8%). His-
tologically, they comprised four cases (4/14; 28.6%) 
of non-aggressive and three cases (3/10; 30%) of ag-
gressive histologic subtypes, respectively. As regards 
to the extent of p16-positivity, it was only focal and 
involved merely 5-20% of total cancer tissue. Notably, 
p16-positive areas occurred only at the edges and at 
the invasive margins of tumor aggregates (Figure 1), 
except for the case of pure infiltrative BCC subtype 
in which they were haphazardly distributed within 
the tumor mass (Figure 2). p16-reactivity was not ob-
served at the center of solid tumor nests.
Immunohistochemical expression of p16 in cuta-
neous BCC is very variable and reported values vary 
greatly between publications. Some authors (2-6) 
demonstrated it in the vast majority (79.2-100%) 
of BCCs. Conscience et al. (7) and Zheng et al. (8) 
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Figure 1. Cytoplasmic positivity for p16 (brown color) in 
nodular BCC at the edge of the tumor nest (magnification 
×20).
Figure 2. An area of infiltrative BCC manifesting diffuse cy-
toplasmic reactivity for p16 (brown color) (magnification 
×20).
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observed it only in 50% and 14.9% of the cases, re-
spectively. Finally, Villada et al. (9) did not report any 
p16-positive BCC in their recent study. Based on the 
literature review (1-9), I speculate that such striking 
discrepancies could be attributed to the following 
reasons: a) different processing technique and meth-
ods used; b) heterogeneity of the biopsy sample size; 
c) case selection bias in terms of the prevalence of 
certain histological BCC subtypes; and d) different 
cut-off values defining the p16-positivity of tumors. 
Biologic and prognostic impact of p16 produc-
tion in cutaneous BCC remains unclear. In principle, 
it would be valuable to know whether BCCs with at 
least focal p16 immunostaining behave differently 
from their p16-negative counterparts. Several studies 
have reported conflicting data regarding a potential 
effect of p16 to invasive properties. Svensson et al. 
(5) showed that p16 expression was associated with 
invasive BCCs with an infiltrative growth pattern. In 
superficial, nodular, and infiltrative histologic sub-
types, they found p16-positivity in 75.0%, 88.8%, and 
100.0% of the cases, respectively. Other authors (2,3) 
did not find a clear relationship between the aggres-
sive growth phenotype of BCC and immunoreactiv-
ity for p16. The data presented herein support the 
results of the latter group, but the present sample of 
p16-positive BCCs was too small to provide a reliable 
conclusion. Nevertheless, evidence of p16-immuno-
reactivity at the edges of tumor nodules and in the 
infiltrative growth pattern was similar with the find-
ings published by Svensson et al. (5).  
Another useful question is whether p16 protein 
production in neoplastic cells depends on the topo-
graphic distribution of lesions and if it may thus be 
influenced by solar exposure. Some authors (1,3,7) 
found that p16 overexpression was associated with 
NMSC arising on sun-exposed areas, suggesting a 
possible induction of p16 protein production by per-
manent ultraviolet radiation. On the other hand, Ital-
ian researchers (4) did not find such an association, 
as among the five BCCs arising on the head and neck 
region only one displayed a high p16 immunoreactiv-
ity. Furthermore, in the study conducted by Villada et 
al. (9), all ten p16-negative BCCs were situated on the 
head and neck. 
Taken together, the biologic and clinical aspects 
of p16 production in cutaneous BCC are still far from 
being clearly understood. I assume that a simple 
quantification of p16 expression in BCC by immuno-
histochemistry is not sufficient for a reliable assess-
ment of the clinicopathologic significances. Further 
studies must be more focused on spatial distribution 
and intensity of p16-positive areas in tumor tissue.
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